The debate over the ideal frequency of pharmaceutical sales calls has persisted for years. While traditional strategies emphasize quantity and maximizing in-person visits, the modern healthcare landscape calls for a more strategic and flexible approach.
Historically, pharmaceutical sales representatives aimed to pack their schedules with 8–10 in-person meetings daily. The rationale was straightforward: the more in-person interactions, the higher the likelihood of driving prescriptions. However, this volume-driven model is becoming increasingly outdated in today's rapidly changing healthcare environment.
A Strategic Approach to Call Frequency
Limited Access
Physicians face increasing time pressures and administrative responsibilities, making frequent in-person meetings more challenging than ever. Over the past decade, studies have repeatedly shown a steady decline in access to pharmaceutical sales representatives.¹
On average, sales calls last only 5–10 minutes, underscoring the need for concise, impactful communication.²
Digital Channels
The emergence of digital communication has created new opportunities for engaging healthcare professionals (HCPs). Industry reports reveal a growing trend among pharmaceutical companies toward virtual meetings and using online content to inform and build relationships.³
Value-Driven Interactions
Healthcare professionals (HCPs) now prioritize engagements that provide meaningful insights and directly contribute to patient care. Research shows that many physicians prefer email as a communication channel, highlighting the growing importance of digital touchpoints.⁴
In today's dynamic healthcare landscape, success hinges on striking the right balance between in-person and digital interactions. reprai is the pharma-native AI built to automate and optimize the operations of pharmaceutical companies, and technologies like it are reshaping how pharmaceutical companies engage with HCPs. These tools enable 24/7 access to information, deliver personalized content, and create virtual engagement opportunities, enhancing both the frequency and quality of communication.
By leveraging technology and embracing innovative, value-driven strategies, pharmaceutical companies can navigate the complexities of modern HCP engagement. A digital-first approach will not only adapt to evolving trends but also ensure stronger, more meaningful connections with healthcare professionals, empowering them to deliver better patient care.
Sources
- ZS Associates AccessMonitor™ (zs.com)
- Pharmaceutical Executive (pharmexec.com)
- Veeva, Digital Trends in the Life Sciences Industry, 2023
- DRG Digital, "ePharma Physician® Report", 2021